Krishna Kant Sharma

Krishna Kant Sharma

Director DIN 08302035
DIN 08302035 First appointment Dec 2018
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Dec 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Krishna Kant Sharma

Data last updated:

Krishna Kant Sharma was a Director at Raviwell Healthcare Private Limited (from 2021) and Director at Cureyo Biotech Private Limited (from 2018).

DIN 08302035
First Appointment 12 Dec 2018
Oldest Company Age 7 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Raviwell Healthcare Private Limited U24299UP2021PTC143817
Director19 Mar 20212021Strike Off
Cureyo Biotech Private Limited U74999UP2018PTC111180
Director12 Dec 20182018Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Raviwell Healthcare Private Limited
Cureyo Biotech Private Limited
Premium access

Shareholding and investment profile for Krishna Kant Sharma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Krishna Kant Sharma

Krishna Kant Sharma was first appointed on 12 Dec 2018 as Director at Cureyo Biotech Private Limited. The most recent appointment on record is 19 Mar 2021 at Raviwell Healthcare Private Limited.

Krishna Kant Sharma held 2 earlier board appointments: Raviwell Healthcare Private Limited (Director, from 19 Mar 2021); Cureyo Biotech Private Limited (Director, from 12 Dec 2018).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available